Considering the distribution of PDEs, PDE3, PDE4, and PDE5 inhibitors might be of a particular benefit in the treatment of ALI/ARDS; however, some improvements might be also demonstrated for other PDE inhibitors. This evidence concerns the gene PDE5A and acute respiratory distress syndrome.